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ABSTRACT 
Methotrexate (MTX) is commonly used in the treatment of malignant diseases and autoimmune and 
chronic inflammatory disorders. Along with its effective therapeutic power, MTX has adverse effects 
on the kidneys. Discovery of new biomarkers is required to improve the early detection of renal 
damage and optimize the effectiveness of treatments. The aim of this study was to evaluate the time 
course of MTX-induced nephrotoxicity and to compare the urinary excretion of the organic anion 
transporter 5 (uOat5) with alterations in other markers of renal function, and to elucidate the 
possible molecular mechanisms involved in uOat5. Animals were exposed to a unique dose of MTX 
(80 mg/kg body weight, intraperitoneal). Experiments were carried out at day 2, 4, 8 or 14 after MTX 
administration. Markers of renal damage, such as creatinine and urea plasma levels, urinary activity 
of alkaline phosphatase, microalbuminuria, urinary excretion of Neutrophil Gelatinase-Associated 
Lipocalin (uNGAL) and histopathology were evaluated. Renal Oat5 and its presence in different urine 
fractions abundance were assessed by Western blotting. uOat5 was significantly increased 2 days 
after MTX treatment, before than any alteration in other parameters of kidney injury or renal 
morphology occurred. uNGAL showed an inverted pattern of urinary excretion compared to uOat5. 
Exosomal pathway is involved in the urinary excretion of Oat5 and depends on the degree of 
damage induced by MTX. These experimental data allow proposing uOat5 as a potential noninvasive 
biomarker for early detection of MTX-induced nephrotoxicity.  
Key words: methotrexate; kidney injury; biomarkers; organic anion transporter 5 
 
1. INTRODUCTION 
Methotrexate (MTX) is one of the most widely used antimetabolite chemotherapeutic to treat 
malignancies, rheumatologic conditions and other chronic inflammatory disorders. MTX is 
worldwide employed due to several characteristics, such as its low price, high response rates and 
therapeutic continuity, and its availability and versatility in dosage and routes of administration 1. 
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observational studies indicate that the most common reason of discontinuing MTX regimens is its 
toxicological profile rather than lack of efficacy 2-5. MTX causes renal dysfunction mainly due to 
direct pharmacological toxicity against renal tubules and/or precipitation of MTX or its metabolites 3-
5. MTX undergoes renal excretion primarily by glomerular filtration and tubular secretion 3,4. Since 
MTX is secreted by the renal tubules, its elimination in urine may be reduced by the concomitant 
administration of other renal secreted drugs. Thus, increased MTX toxicity may occur more often in 
patients with reduced creatinine clearance and those receiving combined therapy 6. 
The organic anion transporter 5 (Oat5, Slc22a19) is exclusively located in the apical 
membranes of proximal tubule cells. Oat5 has been defined as a probenecid-sensitive organic 
anion/dicarboxylate exchanger, which can transport ochratoxin A, dehydroepiandrosterone sulfate 
and estrone-3-sulfate, and can be inhibited by bumetanide, furosemide, penicillin G and by some 
sulfate conjugates 7. Our group was pioneering in detecting Oat5 in urine and proposing its urinary 
excretion (uOat5) as an early indicator of proximal tubule damage in ischemic acute kidney injury, in 
nephropathy induced by mercury or cisplatin, and in the renal damage associated with vascular 
calcification 8-13. Recently, we have also found a dose-related increase in Oat5 urinary abundance in 
MTX-induced renal damage 14. The traditional blood and urinary markers used for diagnosis and 
prognosis of kidney injury are insensitive and nonspecific, which not only delays diagnosis and 
intervention, but also underestimates the degree of injury 15,16. Incorporation of new biomarkers for 
kidney damage into clinical practice might optimize the effectiveness of MTX treatments and the 
prognostic assessment of a given treatment. 
The aim of this study was to evaluate the time course of MTX-induced renal damage and to 
compare uOat5, with alterations in traditional markers of renal injury (such as creatininemia, 
uremia, urinary alkaline phosphatase (AP), microalbuminuria (MAU) and renal histology), and with 
the urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (uNGAL, a novel biomarker of 
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of Oat5 after different times of MTX administration, its expression in renal tissue and in different 
urine fractions have been assessed. 
 
2. RESULTS 
Animals were exposed to 80 mg/kg b.w. i.p. of MTX and experiments were performed after 2, 4, 8 
and 14 days of the injection of the agent or vehicle. 
As it is shown in Figure 1, uOat5 was significantly increased 2 days after MTX injection. 
Interestingly, this biomarker appearance in urine continued elevated until the fourth day of 
treatment. From day 8, Oat5 levels in urine returned to basal values.  
Different traditional parameters of renal function were measured in plasma and urine in 
comparison with time evolution of uOat5. Figure 2 shows urea (A) and creatinine (B) plasma levels, 
as well as creatinine clearance values (C). A significant alteration in M4D group was observed for all 
these parameters, which reflects renal dysfunction on the fourth day after the injection of MTX. 
Renal function ameliorated by the eighth and fourteenth day.  
The histological evaluation of kidneys from Control rats and treated with MTX at each time 
point is shown in Figure 3. In M2D group (Figure 3B) no significant histological damages were 
observed compared to control kidneys. In contrast, on the fourth day after MTX injection, 
considerable damage of renal cells was observed, mainly with a flattened tubular epithelium, tubular 
dilatation and loss of the brush border membrane in proximal tubules (Figure 3C). M8D group 
showed an improvement of the nephron’s architecture with the presence of luminal debris (Figure 
3D). On day 14, renal morphology was fully recovered compared to controls (Figure 3E). The tubular 
injury scores are shown in Figure 3F. 
Urinary AP, MAU and uNGAL were also assessed to evaluate renal injury in comparison with 
uOat5 (Figure 4). No alteration of urinary activity of AP (Figure 4A) was observed. On the other hand, 
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decreased on the second day after MTX treatment, remained low at the fourth and eight day, and 
then started to return to basal levels.  
To understand the origin of Oat5 found in urine, both Oat5 expression and localization were 
evaluated in renal tissue (total homogenates and apical membranes) and in urine fractions (EXO and 
SN) at the time points corresponding to alterations in uOat5 (2nd and 4th day after MTX treatment). 
Figure 5A shows that no alterations were found in the expression of Oat5, in neither renal 
homogenates nor in apical membranes. Immunohistochemistry studies (Figure 5B) showed a strong 
Oat5 labeling associated with the apical plasma membrane in proximal tubule cells. Oat5 
immunostaining was consistent with the results observed by Western blotting in each experimental 
group. The analysis of Oat5 abundance in urine fractions showed a significant increase in EXO 
(similar percentage to that observed in urine), without modifications in SN after 2 days of MTX 
treatment. On the contrary, Oat5 expression was increased in SN and decreased in EXO, respectively 
after 4 days of the drug administration (See Figure 6A). To better understand the mechanism of 
exosomal excretion of Oat5 in the presence of different degrees of MTX-induced renal damage, 
another experimental group of animals was exposed to 360 mg/kg b.w., i.p. of MTX and experiments 
were performed after 2 days, since it has been previously demonstrated a dramatic renal injury with 
this MTX dose 14. In this group of animals, a marked increase of Oat5 abundance was observed in 
total urine and in the soluble urine fraction, while Oat5 expression decreased in EXO (Figure 6B).  
 
3. DISCUSSION  
 
MTX, an antifolate drug, is an effective antineoplastic agent when administered in a high dose. 
When given in low doses, it is an effective drug for rheumatoid arthritis 1,2,6. Side effects of MTX 
treatment are well known and described 3. The most significant risk factor for MTX-toxicity is 
impaired renal function 18,19. At this point, it is important the early diagnosis of kidney injury in order 
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standard to renal failure diagnosis. Nevertheless, this is a suboptimal marker of early renal 
dysfunction and their levels are often not reflective of the glomerular filtration rate, since serum 
concentration is greatly influenced by numerous non-renal factors 17,20. Ongoing investigations focus 
on new biomarkers that can identify renal cells injury when functional impairment is still minimal 
16,17,20. In this regard, renal tubule transporters have gained interest in the biomarker field; for 
instance, aquaporin 2 has been detected in rat and human urine, and recently proposed as a 
potential biomarker for gentamicin-induced nephrotoxicity 21 and the urinary excretion of the Na+/H+ 
exchanger isoform 3 has also been suggested as an acute renal failure marker 22. In this connection 
and attending the fact that the mortality and morbidity associated with acute kidney injury remains 
high despite several therapeutic advances, our laboratory group was pioneering in detecting Oat5 in 
urine and in postulating uOat5 as a noninvasive early biomarker of proximal tubule injury in 
preclinical models of renal and extra-renal pathologies 8-14. 
In the present study, the goal was to evaluate the time course of uOat5 to strengthen the 
hypothesis of its possible role as a more sensitive biomarker of MTX-induced renal damage 
compared to traditional, routinely used biomarkers of nephrotoxicity. To accomplish that objective, 
a time-response study was performed and uOat5 was measured and contrasted to the conventional 
plasma biomarkers and histological changes after a single dose of 80 mg/kg b.w. i.p. of MTX. Studies 
were performed after 2, 4, 8 and 14 days of MTX treatment. On the second day, uOat5 was 
significantly increased as compared with control values while no modifications in any traditional 
renal function markers and no relevant histological findings had still been observed. In contrast, 
plasma levels of urea and creatinine, and creatinine clearance were significantly altered at the fourth 
day post MTX treatment, accompanied by an important impairment of the tubular architecture 
observed by histological studies. By this time point, uOat5 remained elevated, but in a lower 
percentage as compared with the second day. MAU, which is considered an early marker of kidney 
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plasma urea, which reflects that it is not an early marker for MTX-induced nephrotoxicity. Urinary AP 
levels displayed no alterations, showing a lack of sensitivity for the renal damage produced by MTX.  
In this work, it was also assessed uNGAL, which has been investigated extensively as a 
promising early biomarker of kidney injury 17, 24. Under normal conditions, filtered NGAL is almost 
completely reabsorbed by the proximal tubules resulting in minimal uNGAL levels, but it is highly 
expressed in damaged renal tubules and can be quickly detected in urine 25. There are several clinical 
studies and reviews remarking the potential role of the increase urinary excretion of NGAL as a 
reliable diagnostic and prognostic biomarker of acute renal injury of different etiologies 26. 
Surprisingly, the present results showed that not only uNGAL does not increase but decreases at all 
the time points evaluated after MTX administration. MTX has anti-inflammatory and 
immunosuppressive properties by leading a decrease in proinflammatory cytokines production 27. 
Moreover, it is described that MTX suppresses NF-κB activation by releasing adenosine, contributing 
even more to MTX immunosuppressive effects 28. In relation to this, it has also been reported that 
NGAL may be upregulated in a NF-κB-dependent manner 29. In this regard, it is possible to consider 
that the presence of MTX may downregulate NGAL synthesis or liberation as consequence of the 
suppression of NF-κB activation.  
Further studies will be performed to compare the behavior of uOat5 with other novel 
biomarkers of acute kidney injury in this experimental model. To our knowledge, there are few 
reports about the implementation of new biomarkers in urine to diagnose MTX-induced acute 
kidney injury. After different MTX treatments in rats, some studies employed novel biomarkers to 
assess renal damage, besides measuring the traditional ones (such as blood urea nitrogen and 
plasma creatinine). They reported the increase of KIM-1 in renal tissue 30, 31 and an augmented 
urinary NAG 32 and Cys C 33. On the other hand, Carvalho Pedrosa et al. 34 showed a direct correlation 
between MTX serum levels and urinary KIM-1 levels 24 hours after MTX infusion in pediatric 
patients. In the same way, plasma Cys C was useful to evaluate the renal performance before and 
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study proposed to incorporate serum levels of Cys C as a predictive marker of the elimination of MTX 
in high-dose regimens in adult patients with central nervous system primary lymphoma 36. 
In summary, Oat5 urinary excretion significantly increased after 2 days of MTX treatment 
when the other markers of renal function (uremia, creatininemia, creatinine clearance, urinary 
alkaline phosphatase activity, microalbuminuria, and renal morphology) were not modified. Thus, it 
is worth noting that uOat5 has the sensitivity to anticipate renal damage, enhancing its interesting 
behavior as an early biomarker. Coca and Parikh 37 have defined five phases of biomarker 
development for detection of acute kidney injury. Our study is in phase 1, also called discovery 
phase. The data obtained in the present work together with those previously reported by Severin et 
al.14 identifies promising directions of phase 1 that lay the foundations to continue with phase 2 of 
these studies aimed to validate uOat5 as an early biomarker of MTX renal damage.  
In order to understand the mechanism by which Oat5 reaches urine, renal expression of 
Oat5 and its abundance in different urine fractions were evaluated in animals treated with MTX. No 
alterations were observed in renal homogenates or in apical membranes in all the experimental 
groups, despite Oat5 increases in urine. These results were consistent with immunohistochemistry 
studies. Since renal expression of this protein was not modified at any treated group, it is possible to 
suggest that after this toxicant insult, uOat5 depends on a selective apical pathway. Urinary 
exosomes are nanovesicles (50-100 nm) derived from kidney cells and urinary tract and have been 
postulated as a potential source of specific biomarkers of renal diseases 38,39. Previous studies of our 
laboratory suggested the implication of the exosomal pathway as a mechanism by which Oat5 would 
appear in urine 13. In order to determine if the exosomal pathway would participate as the main 
mechanism of Oat5 urinary excretion after MTX treatment, the protein abundance of Oat5 in urinary 
EXO and in the soluble fraction was evaluated. The data obtained suggest that uOat5 is mediated by 
the exosomal pathway when the renal structure and function are still preserved, as observed after 
two days of MTX treatment (M2D group). In addition, it was corroborated that the uOat5 behaves as 
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contrary, when the renal damage was established (four days of treatment, M4D group) and all renal 
parameters were altered, Oat5 was excreted in the soluble fraction. This data would lead to the 
hypothesis that MTX toxicity might affect intracellular signaling mechanisms that are involved in the 
exosomal pathway and therefore in the incorporation of Oat5 into these vesicles. To corroborate 
this hypothesis, another experimental group of animals were exposed to a highly nephrotoxic dose 
of MTX (M360 2D group) 14. In this new group, a marked increase of Oat5 abundance was observed 
in total urine and in the soluble fraction, while Oat5 expression decreased in EXO. According to the 
data presented, it is possible to conclude that the mechanism of uOat5 would depend on the degree 
of injury produced by MTX. The mechanisms by which exosomal cargo is sorting are still unknown. 
Some authors suggested that the NF-κB pathway could be involved in exosomal protein expression, 
leading to an alteration in exosomal pathway 40. Therefore, suppression of NF-κB by adenosine 
release due to MTX treatment might be, at least in part, related to the exosome synthesis and 
liberation. More work is needed to elucidate this thought. 
In conclusion, it is plausible to propose uOat5 as a potential noninvasive early biomarker of 
MTX-induced renal injury that it could be measured in total urine and in urinary exosomes with good 
analytic sensitivity. This work opens new perspectives in using the uOat5 as part of a panel of 
biomarkers of nephrotoxicity.  
 
4. MATERIAL AND METHODS 
4.1 Chemicals and reagents 
Chemicals were purchased from Sigma (St. Louis, MO, USA) and were analytical grade pure. The 
rabbit polyclonal antibody against Oat5 was kindly provided by Prof. N. Anzai (Department of 
Pharmacology, Graduate School of Medicine, Chiba University, Japan). The molecular ruler 
(Kaleidoscope Prestained Standards of molecular mass) was purchased from Bio Rad Laboratories 
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4.2 Animals and treatments 
Male Wistar rats aged 110-130 days from Central Bioterium of Faculty of Biochemical and 
Pharmaceutical Sciences, National University of Rosario were used throughout the study. Animals 
were cared for in accordance with the principles and guidelines for the care and use of laboratory 
animals, recommended by the National Academy of Sciences and published by the National Institute 
of Health (NIH publication 8th, 2011). All experimental procedures were approved by the Faculty of 
Biochemical and Pharmaceutical Sciences Institutional Animal Care and Use Committee (Res. 
N°484/2015). During the experiments, animals were housed in an environment of constant 
temperature (21-23ºC) and humidity with regular light cycles of 12 hours and with free access to tap 
water and food. This study was carried out using only male rats in order to avoid any sex hormones 
influences on the data to be obtained. This work was carried out after the set-up of the working 
conditions (dose and time points chosen for the experiments). Criteria for inclusion: age, sex and 
weight of the animals. Exclusion criteria: animals showing signs of discomfort, distress or stress 
related to incorrect manipulation, not related to renal damage. 
MTX was administrated by intraperitoneal (i.p.) injection of MTX, as was previously reported 
in our laboratory and by other authors 14, 41-44. Intraperitoneal injection is used for small species for 
which intravenous access is challenging, such as Wistar rats, and it can be used to administer large 
volumes of fluid safely 45. 
The animals were randomly divided and treated with a single injection of MTX (80 mg/kg of 
body weight, b.w., i.p.) on day 0. Experiments were carried out in different groups: at day 2 (M2D, n 
= 4), day 4 (M4D, n = 4), day 8 (M8D, n = 4) or day 14 (M14D, n = 4) after MTX administration. 
Corresponding controls to each experimental group injected with vehicle (1 mL/saline kg, b.w., i.p.) 
were processed. As all the tested parameters in control groups (2, 4, 8 and 14 days after vehicle 
administration) were similar, it was decided to consider them as one unified group (Control, n = 10) 
to facilitate the analysis of the results, as previously described 12, 46. This set of animals was used for 
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membranes from kidneys, and another set of rats (n = 4 for each experimental groups) was used for 
histopathological and immunohistochemical studies. An additional group of animals treated with a 
single dose of 360 mg/kg b.w., i.p. of MTX 2 days before the experiments was used (M360 2D, n = 4). 
The rats were placed in metabolic cages 24 h before experiments without food to improve urine 
sample quality, as previously described 14, 47 and with access to water ad libitum through urine 
collection periods. On the day of the experiment, urine was collected. The urinary volume was 
determined gravimetrically and urinary flow rate (Uf) was expressed as mL/24 h/100 g b.w. Then, the 
animals were anesthetized with sodium thiopental (70 mg/kg b.w., i.p.); blood samples were 
obtained by cardiac puncture and kidneys were removed. After surgical procedures, the animals 
received euthanasia using anesthetic overdose and death was confirmed by bilateral thoracotomy.  
 
4.3 Biochemical determinations 
Urine samples were centrifuged at 1000 × g for 10 min to discard whole cells and cellular detritus, 
and the supernatants were used for evaluating AP activity, MAU, creatinine (CrU), as well as the 
protein abundance of Oat5 and NGAL. Plasma samples were used to measure urea (urea p), and 
creatinine levels (creatinine p). Urea p and creatinine p, as well as CrU, AP activity and MAU were 
determined spectrophotometrically, employing commercial kits (Wiener Laboratory, Rosario, 
Argentina). Urinary protein levels of Oat5 and NGAL were evaluated by Western blotting. AP, MAU, 
Oat5 and NGAL in urine were related to urinary creatinine concentration to correct for variations in 
urine production as previously described 10-14. Creatinine clearance (ClCr) was calculated by the 
conventional formula: ClCr = (CrU × Uf) / creatinine p. 
 
4.4 Preparation of total homogenates and apical membranes from kidneys 
Total homogenates and apical membranes were prepared from 4 animals from each experimental 
group. Apical membranes from kidneys were obtained by Mg/EGTA precipitation. Kidneys were 
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mannitol, 5 mM EGTA, 10 mM HEPES-Tris HCl buffer (pH 7.40) and 1 mM phenylmethylsulfonyl 
fluoride (PMSF) for 5 min at top speed in an homogenizer (Glas-Col®, Indiana, USA). From this 
preparation, total renal homogenates were obtained, and aliquots were taken and stored at -80 °C 
until use. Then, MgCl2 was added to the rest of the renal homogenate to a final concentration of 12 
mM and a set of differential centrifugation steps was performed as previously described. Finally, the 
apical membranes were resuspended in 50 mM mannitol, 10 mM Hepes-Tris (pH 7.50) and 1 mM 
PMSF. Aliquots of the membranes were stored immediately at -80 °C until use. Protein quantification 
of samples was performed using the method of Lowry with some modifications, as previously 
described 10-14, 41. 
 
4.5 Isolation of urinary exosomes 
Urinary exosomes were isolated from urine as previously described by Bulacio et al. 13. In brief, 24 h 
urine samples from different experimental groups were centrifuged at 17,000 × g for 15 min at 4 °C 
to remove large membrane fragments, whole cells and other debris. The final pellets (exosome 
fraction, EXO) obtained after the second ultracentrifugation at 200,000 × g for 1 h at 4 °C (OptimaTM 
XL-235 100 K Ultracentrifuge, Beckman Coulter, Inc.; Ti 80 rotor) were resuspended in an 
appropriate volume of isolation solution and frozen at −80 °C un l used. An aliquot of the 
supernatant (SN, also typed as soluble fraction) obtained after the second ultracentrifugation at 
200,000 × g for 1 h at 4 °C was also stored at -80 ºC. Both samples (EXO and SN) were used to assess 
Oat5 abundances. Protein contents were measured, and samples were prepared for electrophoresis 
and immunoblotting as previously described 10-14. 
 
4.6 Electrophoresis and immunoblotting 
Oat5 protein abundances were assessed by electrophoresis and Western blotting in total renal 
homogenates (20 μg of protein), apical membranes (16 μg of protein), total urine (10 μL), EXO (16 μg 










This article is protected by copyright. All rights reserved. 
also determined in total urine samples (10 μL). Ponceau Red was used to verify equal protein loading 
and transfer between lanes as previously described 12,20. In this connection, Romero-Calvo et al. 48 
clearly demonstrated that routine quantification of Ponceau staining is validated as an alternative to 
actin blotting. Nitrocellulose membranes were incubated with a non-commercial rabbit polyclonal 
antibody against rat Oat5 or with a commercial mouse monoclonal antibody against rat NGAL 
(Thermo Fisher Scientific, Rockford, IL, USA). The specificity of Oat5 antibody has been described 
elsewhere 7. Blots were processed for detection using a commercial kit (PierceTM ECL Western 
Blotting Substrate, Thermo Fisher Scientific, Rockford, IL, USA). A densitometric quantification of the 
Western blot signal intensity of membranes was performed (Gel-Pro AnalyzerTM Media Cybernetics, 
Silver Spring, MD, USA). For densitometry of immunoblots, samples from treated rats were run on 
each gel with corresponding control samples and normalized to Ponceau Red. The mean of the 
control value was set as 100 %. Treated groups protein abundances were expressed as percentage of 
the mean control value for that gel. Each value represents mean ± standard error from experiments 
carried out in triplicate on four different tissue derived samples or urine derived samples for each 
experimental group. The protein abundances of Oat5 and NGAL in the urine samples were expressed 
as optical density (O.D., arbitrary units) related to urinary creatinine concentration [(O.D./10 uL)/CrU] 
in order to correct for variations in urine production as previously reported 10, 11, 14, 46, 49. 
 
4.7 Histopathological and immunohistochemistry studies 
For histopathological and immunohistochemistry studies, kidneys were perfused with saline, 
followed by perfusion with periodate-lysine-paraformaldehyde solution (0.01 M NaIO4, 0.075 M 
lysine, 0.0375 M phosphate buffer, with 2 % paraformaldehyde, pH 6.20) through a cannula 
introduced in the abdominal aorta, as previously described 10-14. Some sections were processed for 
routine staining with hematoxylin-eosin to evaluate renal injury. The severity of tubular injury was 
considered as percent of tubules of the section showing a given tubular alteration (tubular 
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was graded as follows: 0, less than 5 %; 1, 5-33 %; 2, 34-66 % and 3, over 66%, as previously 
described 50. Another set of paraffin section was used for Oat5 immunohistochemistry. To this 
purpose, a non-commercial polyclonal antibody against Oat5 (diluted 1:100) was used. Pictures were 
obtained with an optical microscope and are representatives of samples obtained from four animals 
from each experimental group. 
 
4.8 Statistical analysis 
Statistical differences between groups were evaluated using the unpaired Student’s t-test or 
multiple comparisons with one-way ANOVA followed by the Newman-Keuls test. p values of less 
than 0.05 were considered statistically significant. The values are expressed as the means ± standard 
error (SE). For these analyses, GraphPad 6 software (San Diego, California, USA) was used. Student’s 
t-test: (*) p< 0.05 versus Control. Newman-Keuls test: (a) p < 0.05 versus Control, (b) p < 0.05 versus 
M2D, (c) p < 0.05 versus M4D, (d) p < 0.05 versus M8D, (e) p < 0.05 versus M14D.  
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FIGURE LEGENDS 
Figure 1. Urinary excretion of Oat5. Oat5 abundance in urine in Control and treated animals: M2D, 
M4D, M8D and M14D. Densitometric quantifications of Oat5 are expressed in bars (A) and as a time 
line (B).  
 
Figure 2. Urea and creatinine plasma levels and clearance of creatinine in comparison with uOat5. 
Urea (g/L) (A) and creatinine plasma levels (mg/L) (B) and renal clearance of creatinine 
(mL/24h/100g b.w.) (C) (left y axis, continuous line) and in uOat5 (right y axis, dashed line) in Control 
and treated animals: M2D, M4D, M8D and M14D.  
 
Figure 3. Renal Morphology. Optical microscopy photos of kidney histology in Control (A), M2D (B), 
M4D (C), M8D (D) and M14D (E) rats (Hematoxylin-eosin staining). Tubular dilatation (arrow), 
flattened tubular epithelium (star) and luminal debris (arrow head). Tubular alterations score (F). 
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Figure 4. Urinary AP activity, MAU and uNGAL in comparison with uOat5. Urinary AP activity (UI/g 
creatinine) (A), MAU (mg/g creatinine) (B), uNGAL (%) (C) (left y axis, continuous line) and in uOat5 
(right y axis, dashed line) in Control and treated animals: M2D, M4D, M8D and M14D.  
 
Figure 5. Renal expression and immunolabeling of Oat5. Western blotting for Oat5 in renal 
homogenates and apical membranes (A). Kaleidoscope-prestained standards of molecular mass (Mr) 
corresponding to bovine serum albumin (89.4 kDa) and to carbonic anhydrase (38.9 kDa). 
Immunohistochemistry for Oat5 (B) in Control and treated animals: M2D and M4D. Oat5 labeling 
was associated with the apical plasma membranes in proximal tubule cells (arrows). Bars 40 μm. 
 
Figure 6. Oat5 in different urinary fractions. Oat5 abundance in Control and treated animals: M2D, 
M4D, M8D and M14D (A) or Control and M360 2D group (B) in total urine, exosomes (EXO) and 
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